Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Where You Could Sleep With Snorlax in Japan, From MIMARU’s Pokémon Rooms to Grand Hyatt Tokyo’s Limited Pokémon Suite - 2Germany expresses 'great concern' over Israel's new death penalty law
- 3Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- 4Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
- 5Sentimental tree to shine at Arctic League annual broadcast
- Polls open in tense Uganda election amid widespread delays
- Humanity is back at the moon! Artemis 2 astronauts arrive in lunar space
- Ford Is Using a Chinese-Built Van to Fight Europe’s EV Price War
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- What to watch for in weight loss drugs in 2026
- Which salad do you believe is a definitive group pleaser? Vote!
- Canada cancels its 1st moon rover: 'It's hopefully not a lost cause'
- Improving as a Pioneer: Examples from My Vocation
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
